SCHEMBL5962754

SCHEMBL5962754

CCC(CP(=O)(O)O)=C(CC)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GRIK1 P39086 1/20 0.38
GRIA4 P48058 1/20 0.38
GRIK3 Q13003 1/20 0.38
GRIK5 Q16478 1/20 0.38
ENO1 P06733 1/20 0.33
GRIN2D O15399 1/20 0.32
GRIN3B O60391 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
GRIN3A Q8TCU5 1/20 0.32
PGK1 P00558 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903608 1.00 MEN1 (0.42) MEN1LMNAHPGDTSHRBLM
SCHEMBL27561509 0.84 MEN1 (0.44) MEN1LMNAHPGDTSHRBLM
SCHEMBL7755782 0.78 GRIK1 (0.54) TDP1GRIK1GRIA4GRIK3GRIK5
SCHEMBL9678720 0.78 ENO1 (0.34) MEN1LMNAHPGDTSHRBLM
SCHEMBL687974 0.76 CYP2D6 (0.42) MEN1LMNAHPGDTSHRBLM
SCHEMBL9020915 0.76 CYP2D6 (0.42) MEN1LMNAHPGDTSHRBLM
SCHEMBL6653726 0.72 GRIK1 (0.41) MEN1LMNAHPGDTSHRBLM
Butyric Acid SCHEMBL11237544 0.71 FFAR3 (0.38) MEN1LMNAHPGDTSHRBLM
SCHEMBL4091544 0.70 FFAR3 (0.43) TSHRTDP1GRIK1GRIA4GRIK3
SCHEMBL28065698 0.70 FFAR3 (0.43) MEN1TSHRKMT2ATDP1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2644612-B1 Method for producing sanshool TSUMURA & CO (JP) 2016-01-06 EP disclosed
US-8877953-B2 Method for producing sanshool TSUMURA & CO. (JP) 2014-11-04 US disclosed
US-20130261327-A1 METHOD FOR PRODUCING SANSHOOL TSUMURA & CO. (JP) 2013-10-03 US disclosed
EP-2644612-A1 Method for producing sanshool TSUMURA & CO. (JP) 2013-10-02 EP disclosed
US-7115623-B2 PDE IV inhibitors ASKA PHARMACEUTICALS CO., LTD. (JP) 2006-10-03 US disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-20040176365-A1 Pde IV inhibitors ASKA PHARMACEUTICAL CO., LTD. (JP) 2004-09-09 US disclosed
EP-1403270-A1 PDE IV INHIBITORS Grelan Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176365-A1 Pde IV inhibitors PDE3B, PDE3A, PDE2A MEN1 4330/4885LMNA 4459/4885HPGD 138/4885
US-20130261327-A1 METHOD FOR PRODUCING SANSHOOL SCO2, FTH1, CNKSR1 MEN1 3710/4885LMNA 4604/4885HPGD 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.